Vaccine Protection against Simian Immunodeficiency Virus by Recombinant Strains of Herpes Simplex Virus

ABSTRACT An effective vaccine for AIDS may require development of novel vectors capable of eliciting long-lasting immune responses. Here we report the development and use of replication-competent and replication-defective strains of recombinant herpes simplex virus (HSV) that express envelope and Nef antigens of simian immunodeficiency virus (SIV). The HSV recombinants induced antienvelope antibody responses that persisted at relatively stable levels for months after the last administration. Two of seven rhesus monkeys vaccinated with recombinant HSV were solidly protected, and another showed a sustained reduction in viral load following rectal challenge with pathogenic SIVmac239 at 22 weeks following the last vaccine administration. HSV vectors thus show great promise for being able to elicit persistent immune responses and to provide durable protection against AIDS.

[1]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[2]  B. M. Flynn,et al.  Containment of Simian Immunodeficiency Virus Infection: Cellular Immune Responses and Protection from Rechallenge following Transient Postinoculation Antiretroviral Treatment , 2000, Journal of Virology.

[3]  K. Überla,et al.  Antiretroviral Therapy during Primary Immunodeficiency Virus Infection Can Induce Persistent Suppression of Virus Load and Protection from Heterologous Challenge in Rhesus Macaques , 2000, Journal of Virology.

[4]  D. Montefiori,et al.  Protection by Live, Attenuated Simian Immunodeficiency Virus against Heterologous Challenge , 1999, Journal of Virology.

[5]  D. Montefiori,et al.  Role of Immune Responses against the Envelope and the Core Antigens of Simian Immunodeficiency Virus SIVmne in Protection against Homologous Cloned and Uncloned Virus Challenge in Macaques , 1999, Journal of Virology.

[6]  R. Desrosiers.  Strategies used by human immunodeficiency virus that allow persistent viral replication , 1999, Nature Medicine.

[7]  D. Knipe,et al.  Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[8]  J. Heeney,et al.  Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine , 1999, Nature Medicine.

[9]  D. Montefiori,et al.  Highly Attenuated Vaccine Strains of Simian Immunodeficiency Virus Protect against Vaginal Challenge: Inverse Relationship of Degree of Protection with Level of Attenuation , 1999, Journal of Virology.

[10]  J. Berzofsky,et al.  Induction of a Mucosal Cytotoxic T-Lymphocyte Response by Intrarectal Immunization with a Replication-Deficient Recombinant Vaccinia Virus Expressing Human Immunodeficiency Virus 89.6 Envelope Protein , 1998, Journal of Virology.

[11]  D. Coen,et al.  Human Thymidine Kinase Can Functionally Replace Herpes Simplex Virus Type 1 Thymidine Kinase for Viral Replication in Mouse Sensory Ganglia and Reactivation from Latency upon Explant , 1998, Journal of Virology.

[12]  D. Montefiori,et al.  Neutralizing Antibodies in Sera from Macaques Immunized with Attenuated Simian Immunodeficiency Virus , 1998, Journal of Virology.

[13]  R. Desrosiers,et al.  Identification of Replication-Competent Strains of Simian Immunodeficiency Virus Lacking Multiple Attachment Sites for N-Linked Carbohydrates in Variable Regions 1 and 2 of the Surface Envelope Protein , 1998, Journal of Virology.

[14]  R. Means,et al.  A role for carbohydrates in immune evasion in AIDS , 1998, Nature Medicine.

[15]  J. Altman,et al.  Virus-specific CD8+ T cells in primary and secondary influenza pneumonia. , 1998, Immunity.

[16]  E. Paoletti,et al.  Recombinant Vaccine-Induced Protection against the Highly Pathogenic Simian Immunodeficiency Virus SIVmac251: Dependence on Route of Challenge Exposure , 1998, Journal of Virology.

[17]  R. Spaete,et al.  Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs. , 1998, The Journal of infectious diseases.

[18]  P. Luciw,et al.  Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virus. , 1998, The Journal of general virology.

[19]  R. Desrosiers,et al.  Identification of Highly Attenuated Mutants of Simian Immunodeficiency Virus , 1998, Journal of Virology.

[20]  J. Lifson,et al.  Plasma SIV RNA viral load determination by real-time quantification of product generation in reverse transcriptase-polymerase chain reaction. , 1998, AIDS research and human retroviruses.

[21]  R. Desrosiers,et al.  A herpesvirus of rhesus monkeys related to the human Kaposi's sarcoma-associated herpesvirus , 1997, Journal of virology.

[22]  R. Means,et al.  Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus , 1997, Journal of virology.

[23]  R. Desrosiers,et al.  Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus , 1997, Journal of virology.

[24]  F. Miedema,et al.  Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. , 1997, The Journal of general virology.

[25]  R. Desrosiers,et al.  Induction of AIDS by simian immunodeficiency virus lacking NF-kappaB and SP1 binding elements , 1997, Journal of virology.

[26]  B. Gebhardt,et al.  Persistent cytokine expression in trigeminal ganglion latently infected with herpes simplex virus type 1. , 1996, Journal of immunology.

[27]  E. Paoletti,et al.  Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques. , 1996, AIDS research and human retroviruses.

[28]  L. Morrison,et al.  Mechanisms of immunization with a replication-defective mutant of herpes simplex virus 1. , 1996, Virology.

[29]  Ting Liu,et al.  Inflammatory infiltration of the trigeminal ganglion after herpes simplex virus type 1 corneal infection , 1996, Journal of virology.

[30]  J. Mullins,et al.  Simian Immunodeficiency Virus DNA Vaccine Trial in Macaques , 1995, Journal of virology.

[31]  E. Cantin,et al.  Gamma interferon expression during acute and latent nervous system infection by herpes simplex virus type 1 , 1995, Journal of virology.

[32]  D. Easty,et al.  Immune cell infiltration and persistence in the mouse trigeminal ganglion after infection of the cornea with herpes simplex virus type 1 , 1995, Journal of Neuroimmunology.

[33]  D. Montefiori,et al.  Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge , 1994, Journal of virology.

[34]  S. Inglis,et al.  Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted , 1994, Journal of virology.

[35]  L. Morrison,et al.  Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection , 1994, Journal of virology.

[36]  R. Desrosiers,et al.  Titration and characterization of two rhesus-derived SIVmac challenge stocks. , 1994, AIDS research and human retroviruses.

[37]  R. Montelaro,et al.  Lentivirus envelope sequences and proviral genomes are stabilized in Escherichia coli when cloned in low-copy-number plasmid vectors. , 1993, Gene.

[38]  N. Haigwood,et al.  Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection , 1993, Journal of virology.

[39]  D. Knipe,et al.  Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection , 1992, Journal of virology.

[40]  L. Corey,et al.  Human CD8+ herpes simplex virus-specific cytotoxic T-lymphocyte clones recognize diverse virion protein antigens , 1992, Journal of virology.

[41]  R. Desrosiers,et al.  The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus. , 1990, AIDS research and human retroviruses.

[42]  B. Roizman,et al.  In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). , 1990, The Journal of infectious diseases.

[43]  D. Knipe,et al.  Genetic evidence for two distinct transactivation functions of the herpes simplex virus alpha protein ICP27 , 1990, Journal of virology.

[44]  D. Knipe,et al.  Genetic evidence for multiple nuclear functions of the herpes simplex virus ICP8 DNA-binding protein , 1989, Journal of virology.

[45]  R. Desrosiers,et al.  Long-term persistent infection of macaque monkeys with the simian immunodeficiency virus. , 1987, The Journal of general virology.

[46]  D. Knipe,et al.  Definition of a series of stages in the association of two herpesviral proteins with the cell nucleus , 1982, Journal of virology.

[47]  B. Roizman,et al.  Molecular genetics of herpes simplex virus. III. Fine mapping of a genetic locus determining resistance to phosphonoacetate by two methods of marker transfer , 1979, Journal of virology.

[48]  J. Walboomers,et al.  A new method for the isolation of herpes simplex virus type 2 DNA. , 1976, Virology.

[49]  M. Rola-Pleszczynski,et al.  Depressed specific cell-mediated immunity to Herpes simplex virus type 1 in patients with recurrent herpes labialis , 1975, Infection and immunity.

[50]  E. Petersen,et al.  Herpes simplex viruses. , 2009 .